SB-366791 has been used as a transient receptor potential cation channel subfamily V member 1 (TRPV1) antagonist:
to infer the in vitro and in vivo pharmacology of (E)-3-(4-t-butylphenyl)-N-(2,3-dihydrobenzo[b][1,4]dioxin-6-yl)acrylamide (AMG 9810)[1]
to study its effects on sodium hydrogen sulfide (NaHS) or capsaicin-induced contractile activity[2]
to study the inhibitory potency of phoneutria toxin (PnTx3-5) (native and recombinant) on various responses mediated by transient receptor potential cation channel subfamily V member 1 (TRPV1)[3]
Biochem/physiol Actions
SB-366791 might exhibit analgesic properties on bone cancer-related pain behavior.[4]
Vanilloid receptor-1 (TRPV1) antagonist.
Features and Benefits
This compound was developed by GlaxoSmithKline. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.
TRPV1 is a cation channel expressed in peripheral nociceptive pathways and its activation can trigger nociception signals to the brain. Ketamine is an intravenous anesthetic routinely used for anesthesia induction and with potent analgesic activity. Despite its proven depressant action
Journal of translational medicine, 17(1), 346-346 (2019-10-24)
Tibial fracture is associated with inflammatory reaction leading to severe pain syndrome. Bradykinin receptor activation is involved in inflammatory reactions, but has never been investigated in fracture pain. This study aims at defining the role of B1 and B2-kinin receptors
Pharmacological investigation of hydrogen sulfide (H2S) contractile activity in rat detrusor muscle
Patacchini R, et al.
European Journal of Pharmacology, 509(2-3), 171-177 (2005)
SB366791, a TRPV1 antagonist, potentiates analgesic effects of systemic morphine in a murine model of bone cancer pain
Niiyama Y, et al.
British Journal of Anaesthesia, 102(2), 251-258 (2009)
The Journal of pharmacology and experimental therapeutics, 313(1), 474-484 (2004-12-24)
The vanilloid receptor 1 (VR1 or TRPV1) is a membrane-bound, nonselective cation channel expressed by peripheral sensory neurons. TRPV1 antagonists produce antihyperalgesic effects in animal models of inflammatory and neuropathic pain. Here, we describe the in vitro and in vivo
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
